EU regulator backs Eisai-Biogen Alzheimer’s drug Sub: Sci Sec: Health Context: The European Union’s drugs regulator, the European Medicines Agency (EMA), recently recommended the approval of Leqembi (a drug developed by Eisai and Biogen) for patients with early-stage Alzheimer’s disease. This decision marks a reversal from its initial rejection four months ago and […]